Dermatology RSS : Gourt

Pacific Northwest City of 150k, 'The Emerald City', 99% Outpatient, #3349 :: Oregon :: Timeline Recruiting

Upgrade your quality of life and downgrade your stress by relocating to this fabulous city. Ramp up quickly and be part of a stable, cohesive team anxiously awaiting your services. You will love working

Stockton Near Sacramento and San Francisco- Northern CA :: California :: California Physician Opportunities

GM-1163 Wanted Dermatologist - wanted for Stockton, near San Francisco and Sacramento. Stockton is one of California's larger cities. The Gateway to the Sacramento Delta, participate in world

Modesto, Near San Francisco & Sacramento - Northern CA :: California :: California Physician Opportunities

GM-1025 Wanted Dermatologist - metro just 60 minutes from the San Francisco Bay, Large population good schools, great weather, professional symphony and plenty of outdoors activities,

Northern Jersey close to Shore :: New Jersey :: Booth-Yellin Physician Recruitment

A Multi-specialty group practice located less than a hour to NYC and only 25 miles from the NJ beach has a opening for a BE/BC Dermatologist to join them. Practice offers several employment options including

30 minutes from Boston Mass :: Massachusetts :: Healthcare Recruitment Counselors, LLC

Dermatologist Boston area Hospital We are currently recruiting for a BC/BE Dermatologist for our Boston area Hospital. The ideal candidate will be BC/BE American trained but will look at oversea schools

Eastern Cleveland suburb :: Ohio :: Nationwide Physician Recruitment

This is an outstanding opportunity to join a progressive dermatologist in a private practice that offers the newest treatments to patients. You will be joining a very successful practice with a 4-6 week

Opportunity in Charlotte :: North Carolina :: Enterprise Medical Service

Seeking a general Dermatologist to join one of the areas largest multi-specialty groups. General dermatology practice with a little cosmetic and no MOHS surgery or specialist Over 10 practice locations,

Eastern North Carolina :: North Carolina :: MedPro Search - Recruiting For Physician Jobs

Dermatology Physician needed in Eastern North Carolina Community. Walk into busy practice with income guarantee, marketing, relocation, etc. General Dermatology practice. No MOHS surgery available.

Great Location :: Kansas :: MedBizJob.com

We are currently seeking a BC/BE Dermatologist to practice in Dermatological and Medical Aesthetics care in a well organized and growing private practice. If you are interested in an opportunity that

Corvallis, OR :: Oregon :: Enterprise Medical Service

Well established multi-specialty group along the beautiful Oregon coast in need of 2nd Dermatologist due to patient demand. New medical office building under construction with state of art equipment.

Long Island :: New York :: Winston Staffing

Seeking BC Dermatologist's for practice opportunities in NY Long Island & NNJ with a large and prestigious private group. If you are an experienced general dermatology/ cosmetic/laser speciality, we would

Nationwide :: Texas :: Physician Referral Network

Physician Referral Network is your best source to learn about the latest practice opportunities. We are not a recruiting firm, so we promise you'll never be pressured to look at or take a position that

Northeast :: Arkansas :: Horton Smith Associates

Our client seeks a Dermatologist for a general practice with no cosmetics. There is only one other dermatologist serving a population of over 600,000, and new patients have a four-month wait. There is

Northern :: California :: Fidelis Partners

DERMATOLOGY NORTHERN CALIFORNIA $400,000 FIRST YEAR TOTAL 6 MONTH LOCUMS AVAILABLE AS WELL Join the oldest primary care group (instant referrals) north of Sacramento * $350,000 Salary * $25,000

New York :: New York :: Winston Staffing

Dermatologist-New York City major upscale prestigious multi specialty Private Practice located in midtown seeks a dermatologist to complete their helath and wellness oriented physician team. Well established

Central :: South Carolina :: Medical Search International

DERMATOLOGY - SOLO WITH HOSPITAL ASSISTANCE - LAKE FRONT COMMUNITY - GREAT PLACE TO LIVE & PRACTICE - We are seeking a Dermatologist to start a new private practice. Currently there are two Dermatologists

Midwest :: Nebraska :: Excel Recruiting Services

BC/BE Dermatologist needed in solo position or to join existing practice. Opportunity in MOHS or cosmetics in addition to general dermatology. Shared call with competitive salary, benefits, relocation

Midwest :: Illinois :: Excel Recruiting Services

BC/BE Dermatologist for employed position with great referral base. Very light call. General dermatology position with some cosmetics, no MOHS. There is a huge patient need - can creater a great practice.

Dallas :: Texas :: Phyllis Vajda & Associates, LLC

Opportunity Well-established private practice seeks to replace third Pulmonary/Critical Care physician for primarily hospital-based practice with some clinic work in office attached to the hospital.

Maine :: Maine :: Healthcare Recruitment Counselors, LLC

Dermatologist-Maine Family Residency Program is seeking 2 Clinical Dermatologists to join the faculty of the residency. We offer an outstanding financial package with an incentive component, and successful

Melanoma Associated With Long-term Voriconazole Therapy: A New Manifestation of Chronic Photosensitivity [Observation]

Background Voriconazole is a triazole antifungal agent approved by the US Food and Drug Administration for serious fungal infections, including with Aspergillus, Fusarium, Pseudallescheria, and Scedosporium species. In initial clinical trials, approximately 2% of patients developed cutaneous reactions, including photosensitivity, cheilitis, and xerosis. Subsequent reports have implicated voriconazole as a cause of severe photosensitivity and accelerated photoaging, pseudoporphyria cutanea tarda, and aggressive squamous cell carcinoma.Observation We report 5 melanoma in situ lesions in the setting of extreme photosensitivity associated with long-term voriconazole therapy.Conclusions We recommend surveillance for skin cancer formation in all patients who require long-term voriconazole treatment, particularly those who manifest signs or symptoms of photosensitivity or chronic photodamage. Further study of the mechanism underlying voriconazole photosensitivity and oncogenesis is warranted.Published online January 18, 2010 (doi:10.1001 /archdermatol.2009.362).

Publishing Online Ahead of Print [Announcement]

About This Journal [About This Journal]

This Month in Archives of Dermatology [This Month in Archives of Dermatology]

Memorial to Dr. Ernest Besnier from the New York Dermatological Society [Archives a Century Ago]

Basal Cell Nevus Syndrome: A Brave New World [The Cutting Edge]

Anti-Bullous Pemphigoid 180 and 230 Antibodies in a Sample of Unaffected Subjects [Study]

Objective To evaluate the prevalence of autoantibodies against 2 hemidesmosomal proteins typically found in patients with bullous pemphigoid (BP), BP antigen II (BP180) and BP antigen I (BP230), in persons without BP. Design Cross-sectional study. Setting Academic medical center. Patients An age- and sex-stratified, random, population-based sample of local county patients seen during 2007: 20 men and 20 women per decade of age (from age 20 to 89 years) and 57 patients (33 women and 24 men) aged 90 to 99 years. Intervention Stored serum samples were retrieved for analysis by enzyme-linked immunosorbent assay and indirect immunofluorescence. Main Outcome Measure Presence of circulating autoantibodies to BP180 and BP230. Results Of the 337 study patients, 25 (7.4%) were positive for 1 or both autoantibodies; these 25 samples all tested negative with indirect immunofluorescence. Autoantibody levels did not vary by age or sex. Conclusions Bullous pemphigoid has a higher incidence in the elderly population, but the prevalence of antibodies to BP180 and BP230 did not increase significantly with age or vary by sex in this population-based sample. Other exogenous factors may affect the development of these autoantibodies in a population without clinically evident immunobullous disease, including limitations inherent to the test (false-positive rate).

Incidence of Dermatomyositis and Clinically Amyopathic Dermatomyositis: A Population-Based Study in Olmsted County, Minnesota [Study]

Objectives To identify new and existing cases of dermatomyositis and its subtypes in Olmsted County, Minnesota, from 1976 through 2007, and to establish a population-based estimate of the incidence and prevalence of dermatomyositis and amyopathic dermatomyositis. Design Retrospective population-based study. Setting Community-based epidemiology project. Patients Patients with a diagnosis of dermatomyositis were identified from the Rochester Epidemiology Project. Main Outcome Measures Incidence of dermatomyositis and clinically amyopathic dermatomyositis and risk of malignancy in clinically amyopathic dermatomyositis. Results Of the 29 patients identified, 6 (21%) had the clinically amyopathic subtype of dermatomyositis and 22 (76%) were female. Overall age- and sex-adjusted incidence of dermatomyositis including all subtypes was 9.63 (95% confidence interval [CI], 6.09-13.17) per 1 million persons and 2.08 (95% CI, 0.39-3.77) per 1 million persons for clinically amyopathic dermatomyositis. Age- and sex-adjusted prevalence for all subtypes of dermatomyositis was 21.42 (95% CI, 13.07-29.77) per 100 000 persons. Eight patients (28%) had a malignant condition during the study period; the risk of malignancy (odds ratio) for classic dermatomyositis compared with clinically amyopathic dermatomyositis was 4.61 but was not statistically significant (95% CI, 0.22-96.09) (P = .44). Conclusions Dermatomyositis is a rare disease, and clinically amyopathic dermatomyositis represents an estimated 20% of all dermatomyositis cases. Larger population-based studies are needed to estimate the risk of malignancy associated with subtypes of dermatomyositis, particularly clinically amyopathic dermatomyositis.

Comparison of Treatment of Cherry Angiomata With Pulsed-Dye Laser, Potassium Titanyl Phosphate Laser, and Electrodesiccation: A Randomized Controlled Trial [Study]

Objective To assess the comparative efficacy of energy treatments in resolving cherry angiomata. Design Rater-blinded randomized controlled trial. Setting Outpatient dermatology clinic in an urban referral academic medical center. Participants Fifteen healthy adults aged 21 to 65 years were enrolled. Two eligible individuals who were approached declined to participate, and no one enrolled was withdrawn for adverse effects. Interventions For each participant, 3 areas on the torso were demarcated such that each area contained 4 cherry angiomata. Each area was then randomly assigned to receive 1 of the 3 treatments: pulsed-dye laser (PDL) (595 nm), potassium titanyl phosphate (KTP) laser (532 nm), or electrodesiccation. Two treatments spaced 2 weeks apart were delivered to each area. Main Outcome Measures Standardized photographs from before treatment and 3 months after the last treatment were evaluated for color and texture on visual analog scales. Results Mean change in color was a significant improvement of 7.77 (P < .001), but there was no significant difference across treatment arms (P = .19). Mean change in texture was a significant improvement of 6.23 (P < .001), and the degree of textural change also differed across treatments (P < .001). In pairwise comparisons, cherry angiomata treated with electrodesiccation were significantly less improved than were those receiving KTP laser (P = .003) and those treated with PDL (P = .001). The effects of KTP laser and PDL on texture were not different (P = .50). Conclusions Cherry angiomata can be effectively treated with electrodesiccation and with laser. Laser, especially PDL, may minimize the likelihood of treatment-associated textural change. Trial Registration clinicaltrials.gov Identifier: NCT00509977

October 2009 Archives Web Quiz Winner [Archives Web Quiz Winner]

In Vitro and In Vivo Laser Treatments of Tattoos: High Efficiency and Low Fluences [Study]

Objective To analyze the absorption of tattoo inks related to their in vivo and in vitro behavior under laser irradiation to improve laser-assisted tattoo removal. Design The absorption of 21 tattoo inks in a wavelength range from 300 to 800 nm was characterized by reflection spectroscopy from samples consisting of inks mixed in gelatin. Tattoo inks were removed in vitro using pulsed laser radiation with different variables, and morphologic analysis of the irradiated areas was performed. Setting An interdisciplinary laser laboratory with a common industrial project with the Spanish company Milesman S.A. Participant One person was voluntarily tattooed with 2 of the studied inks. Main Outcome Measures (1) First approach to the optimum dose for pigment removal in in vitro models. (2) Correlation between the in vitro and in vivo situations at the optimum dose. Results Reflection spectroscopy facilitated selection of the most adequate laser wavelengths for tattoo removal. Red, orange, and rose inks were successfully lightened at 532 nm with 0.6 J/cm2; brown at 1064 nm with 0.3 J/cm2; yellow and green at 448 nm with 2.6 J/cm2; and blue at 600 nm with 0.9 J/cm2. Similar colors in in vitro and in vivo tattoos responded with the same efficiency to the laser variables. Conclusions High efficiency is reached in the removal of in vivo tattoos by using an irradiation wavelength at which the percentage of reflection from the pigment is minimal. Under this condition, laser pulses can be used with a low fluence, minimizing adverse effects and clinical time.

Volunteering With Health Volunteers Overseas [Announcement]

Recent Trends in Systemic Psoriasis Treatment Costs [Study]

Objectives To analyze the current total cost of systemic therapy for psoriasis and to compare annual trends in the cost of both generic and brand-name therapies with trends in the Consumer Price Index–Urban since 2000. Design A cost model was developed that includes costs for prescription drugs, office visits, and suggested laboratory tests and monitoring procedures. Annual trends in psoriasis drug costs from 2000 through 2008 were analyzed by calculating the percentage change in the average wholesale price from the previous year; these values were compared with changes in the yearly Consumer Price Index–Urban values. Setting The United States. Main Outcome Measures Total annual costs for systemic psoriasis therapies and trends in cost compared with the trends in Consumer Price Index–Urban values (equivalent to inflation). Results Current total annual costs for systemic psoriasis therapies ranged from $1197 (methotrexate) to $27 577 (alefacept, two 12-week courses). Trends in the average wholesale price of brand-name psoriasis therapies from 2000 through 2008 demonstrate an average increase of 66% (range, –24% to +316%); thus, costs of several brand-name psoriasis drugs greatly outpaced the rates of inflation for all items and all prescription drugs. Conclusions Despite the higher monitoring costs associated with traditional systemic therapies, annual costs of biologics exceed those of other available therapies. Current trends demonstrate that systemic psoriasis therapy costs are increasing at a much higher rate compared with general inflation.

The Safety and Efficacy of Pimecrolimus, 1%, Cream for the Treatment of Netherton Syndrome: Results From an Exploratory Study [Observation]

Background Impaired skin integrity in patients with Netherton syndrome (NS) results in significant systemic absorption of topically applied medications. Some have advocated the administration of pimecrolimus, 1%, topical cream for the treatment of patients with NS. Insufficient data exist with regard to its safety, systemic absorption, and efficacy. Observations An exploratory study was conducted involving 3 children with NS who received twice-daily application of pimecrolimus, 1%, cream over 18 months. There were no notable abnormalities in hematologic or chemistry profiles. Blood levels of pimecrolimus ranged from 0.625 to 7.08 ng/mL, with peak levels reached during the first month in all 3 patients. Dramatic reductions were observed in the Netherton Area and Severity Assessment, Eczema Area and Severity Index, Investigator Global Evaluation of Disease, and pruritus scores compared with baseline levels. Conclusions Use of pimecrolimus, 1%, cream was well tolerated and demonstrated marked improvements in nearly all of the parameters evaluated. Patients treated with pimecrolimus responded rapidly, within the first month of treatment, and improvement persisted throughout the study period. In adult patients receiving oral pimecrolimus, blood levels as high as 54 ng/mL for 3 months have not shown clinically significant immunosuppression. Absorption of pimecrolimus, 1%, cream was detectable, but levels were much lower than expected even when applied to 50% of total body surface area. Larger studies are warranted to determine the safety and efficacy of pimecrolimus, 1%, cream in the treatment of NS. Trial Registration clinicaltrials.gov Identifier: NCT00208026

Buschke-Ollendorff Syndrome: Absence of LEMD3 Mutation in an Affected Family [Observation]

Background Buschke-Ollendorff syndrome (BOS), an autosomal dominant disorder, features small, acquired, asymptomatic, symmetrical foci of osteosclerosis detected radiographically in epimetaphyseal bone (osteopoikilosis) (OPK) together with connective tissue nevi or juvenile elastomas. Heterozygous, loss-of-function, germline mutation in the LEMD3 gene (which encodes an inner nuclear membrane protein called LEMD3, or MAN1) has been repeatedly documented in patients with BOS or OPK. Observations We describe a father and son with multiple yellowish papules and nodules coalescing into cobblestone nevoid plaques consistent with nevus elasticus. Radiographs of the father show multiple, small, bone islands within the hands, wrists, distal femurs, proximal tibias, and left distal fibula consistent with OPK. Although the clinical findings are diagnostic of Buschke-Ollendorf syndrome, analysis of the LEMD3 gene showed no exonic mutations. Conclusion Absence of LEMD3 mutation in the exons and splice sites of a family with BOS suggests that there is genetic heterogeneity for this disorder.

Cock's Peculiar Tumor [Notable Notes]

Disfiguring Generalized Verrucosis in an Indonesian Man With Idiopathic CD4 Lymphopenia [Observation]

Background Human papillomavirus (HPV) infections cause a spectrum of clinical disease states, depending on the causative HPV and the characteristics of the infected host, especially the status of cell-mediated immunity. Generalized verrucosis is an unusual clinical presentation of a disseminated HPV infection associated with severe immunodeficiency status. Observations We present a case of extreme disfigurement associated with an HPV-2 (common wart virus) infection. Virologic studies, immune status of the patient, and treatment(s) are summarized. Conclusions The severe disfigurement of this patient was a result of an underlying severe immunodeficiency, permissive for a disseminated HPV-2 infection that was allowed to progress for many years before the initiation of therapy. Such a rare case illustrates the natural history of generalized verrucosis in the setting of severe immunodeficiency in the absence of sustained medical interventions. Medical and surgical treatments resulted in marked improvement in the general health of this patient, as well as improvement of the disfigurement that resulted from the generalized verrucosis.

Prevalence of Autoantibodies to Bullous Pemphigoid Antigens Within the Normal Population [Editorial]

Clinically Amyopathic Dermatomyositis: What Can We Now Tell Our Patients? [Editorial]

Ulcerated Facial Nodules in a Renal Transplant Recipient--Quiz Case [Off-Center Fold]

Ulcerated Facial Nodules in a Renal Transplant Recipient--Diagnosis [Off-Center Fold]

Pruritic Reticular Eruption on the Chest of a 24-Year-Old Woman--Quiz Case [Off-Center Fold]

Pruritic Reticular Eruption on the Chest of a 24-Year-Old Woman--Diagnosis [Off-Center Fold]

Erythematous Erosive Patch on the Left Nipple--Quiz Case [Off-Center Fold]

Erythematous Erosive Patch on the Left Nipple--Diagnosis [Off-Center Fold]

Hemochromatosis and Bilateral Yellow Papules of the Neck--Quiz Case [Off-Center Fold]

Hemochromatosis and Bilateral Yellow Papules of the Neck--Diagnosis [Off-Center Fold]

Lack of Wnt5A Expression in Merkel Cell Carcinoma [Research Letters]

Combined Treatment With Rituximab and Anthracycline-Containing Chemotherapy for Primary Cutaneous Large B-Cell Lymphomas, Leg Type, in Elderly Patients [Research Letters]

Comparing the Efficacy of an In-Person Intervention With a Skin Self-examination Workbook [Research Letters]

A Simple Solution to the Common Problem of Ecchymosis [Research Letters]

Pretibial Lymphoplasmacytic Plaque in Children [Correspondence]

A Novel Mutation in the TAP2 Gene in Bare Lymphocyte Syndrome: Association With Metastatic Cutaneous Squamous Cell Carcinoma [Correspondence]

Hereditary Benign Telangiectasia: Two Families With Punctate Telangiectasias Surrounded by Anemic Halos [Correspondence]

Therapeutic Effect of Clopidogrel on Cutaneous Polyarteritis Nodosa [Correspondence]

The Dermatologic Manifestation of Novel Influenza A(H1N1) [Correspondence]

Complete and Durable Clinical Response of Malignant Pyoderma to Tacrolimus in Combination With Dapsone and Prednisone [Correspondence]

Reversal of Canities [Correspondence]

Dermoscopic Subpatterns of Ashy Dermatosis Related to Lichen Planus [skINsight]